Valsts: Īrija
Valoda: angļu
Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)
Attenuated canine distemper virus, strain ba5; Attenuated canine adenovirus type 2, strain dk13; Attenuated canine parvovirus, strain cag2; Attenuated canine parainfluenza virus type 2, strain cgf 2004/75
Boehringer Ingelheim Vetmedica GmbH
QI07AD04
Attenuated canine distemper virus, strain ba5; Attenuated canine adenovirus type 2, strain dk13; Attenuated canine parvovirus, strain cag2; Attenuated canine parainfluenza virus type 2, strain cgf 2004/75
.
Lyophilisate for suspension for injection
POM: Prescription Only Medicine as defined in relevant national legislation
canine distemper virus + canine adenovirus + canine parvovirus + canine parainfluenza virus
Authorised
2005-10-28
Health Products Regulatory Authority 15 July 2020 CRN009VN8 Page 1 of 4 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican DHPPi lyophilisate for suspension for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One dose of lyophilisate contains: ACTIVE SUBSTANCES MINIMUM MAXIMUM Attenuated canine distemper virus, strain BA5 10 4.0 CCID 50 * 10 6.0 CCID 50 Attenuated canine adenovirus type 2, strain DK13 10 2.5 CCID 50 10 6.3 CCID 50 Attenuated canine parvovirus type 2, strain CAG2 10 4.9 CCID 50 10 7.1 CCID 50 Attenuated canine parainfluenza virus type 2, strain CGF 2004/75 10 4.7 CCID 50 10 7.1 CCID 50 (*CCID 50 : 50% cell culture infective dose) For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Beige to pale yellow lyophilisate for suspension for injection 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunisation of dogs to: - prevent mortality and clinical signs caused by canine distemper virus (CDV), - prevent mortality and clinical signs caused by infectious canine hepatitis virus (CAV), - reduce viral excretion during respiratory disease caused by canine adenovirus type 2 (CAV-2), - prevent mortality, clinical signs and viral excretion caused by canine parvovirus (CPV)*, - reduce viral excretion caused by canine parainfluenza virus type 2 (CPiV), Onset of immunity: 2 weeks for all strains Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains. Current available challenge and serological data show that protection for distemper virus, adenovirus and parvovirus* lasts for 2 years after primary vaccination course followed by a first annual booster. Any decision to adapt the vaccination schedule of this veterinary medicinal product needs to be made on a case by case basis, taking into account the vaccination history of the dog and the epidemiological context. *Protection has been demonstrated against canine parvovirus type 2a, 2b Izlasiet visu dokumentu